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Available online at www.sciencedirect.comNarcolepsy is a neurological disorder characterized by
excessive daytime sleepiness, cataplexy, hypnagonic
hallucinations, sleep paralysis, and disturbed nocturnal sleep
patterns. Narcolepsy is caused by the loss of hypocretin
(orexin)-producing neurons in the lateral hypothalamus.
Evidence, such as a strong association with HLA DQB1*06:02,
strongly suggests an autoimmune basis targeting hypocretin
neurons. Genome-wide association studies have strengthened
the association between narcolepsy and immune system gene
polymorphisms, including the identification of polymorphisms
in the T cell receptor alpha locus, TNFSF4 (also called OX40L),
Cathepsin H (CTSH) the purinergic receptor P2RY11, and the
DNA methyltransferase DNMT1. Recently, attention has been
raised regarding a spike in cases of childhood narcolepsy in
2010 following the 2009 H1N1 pandemic (pH1N1) in China and
vaccination with Pandemrix, an adjuvanted H1N1 vaccine that
was used in Europe. How the immune system may be involved
in disease initiation and/or progression remains a challenge to
researchers. Potential immunological pathways that could lead
to the specific elimination of hypocretin producing neurons
include molecular mimicry or bystander activation, and are
likely a combination of genetic and environmental factors, such
as upper airway infections.
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Narcolepsy and the loss of hypocretin
Narcolepsy affects approximately 0.02% of the popu-
lation worldwide. Narcoleptic patients frequently have
severe sleepiness, which makes remaining awake during
activities that demand an alert state particularly difficult.
Additionally, these individuals commonly have fragments
Open access under CC BY-NC-ND license.www.sciencedirect.com of Rapid Eye Movement (REM) sleep that intrude into
wakefulness, such as hypnagogic (dream-like) hallucina-
tions as they drift off to sleep, as well as brief episodes of
cataplexy (muscle paralysis) triggered by strong emotions
[1–4]. One of the most important breakthroughs in elu-
cidating the cause of narcolepsy came with the discovery
of hypocretins (orexins) [5,6,7]. Hypocretins are exclu-
sively synthesized in the lateral hypothalamus (LH) and
are derived from a single protein precursor named prepro-
hypocretin. Prepro-hypocretin is enzymatically cleaved
into two peptides, hypocretin 1 and 2 (also called orexin A
and B), which are comprised 33 and 28 amino acids
respectively. There are two cloned hypocretin receptors,
HCRTR1 and HCRTR2, both of which are serpentine G-
protein-coupled receptors [6]. Hypocretin-secreting
neurons project from the LH throughout the central
nervous system (CNS) to neurons involved in the regu-
lation of feeding, sleep-wakefulness, neuroendocrine
homeostasis, and autonomic regulation [8,9]. Hypocretin
knockout mice and dogs with null mutations in the
HCRTR2 gene develop narcoleptic symptoms, indicat-
ing that the loss of this peptide is causal for development
of narcolepsy.
The loss of hypocretin has also been reported by numer-
ous clinical studies of narcoleptic individuals
[10,11,12,13,14,15].
Narcoleptic patients typically have low hypocretin cere-
brospinal fluid (CSF) levels which can be explained by
the loss of over 90% of their hypocretin-producing
neurons, a process that has been associated with narco-
leptic onset [16]. This loss of hypocretin-producing cells
is seemingly selective, rather than general or regional
destruction, as intermingling melanin-concentrating
neurons appear unaffected in the same narcoleptic
patients [14,15]. This specific depletion of hypocretin-
secreting neurons led to the hypothesis that narcolepsy is
an autoimmune driven process within the hypothalamus
[17–19].
Increased onset of narcolepsy following
infections
It has become increasingly clear that environmental
factors play an important role in the development and
progression of a variety of autoimmune conditions [20].
Particular attention has focused on the connection be-
tween infections and disease pathophysiology [21].Current Opinion in Neurobiology 2013, 23:767–773
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common upper airway infections, including those
caused by Streptococcus pyogenes and the influenza A virus
[22,23,24]. In China, the onset of narcolepsy in chil-
dren appears to follow seasonal patterns, with significant
increases in cases reported in the months following
winter-related infections [24]. Streptococcal infec-
tions have also been associated with various
neurological autoimmune disorders, including Syden-
ham Chorea, suggesting that certain immunological
responses to infection may result in specific neurological
damage [25]. Epidemiological studies have revealed
that individuals infected with streptococcus are more
than five times as likely to develop narcolepsy, with
streptococcus-specific antibodies found in 65% of nar-
coleptic patients as compared to 26% of age-matched
controls  [22,23]. The development of narcolepsy in
association with upper airway infections could result
from various processes, including molecular mimicry
and bystander activation. Molecular mimicry would
involve processing and presenting bacterial and viral
peptides in the context of DQB1*06:02, which would
activate a population of cross-reactive T cells present in
predisposed  individuals. Bystander activation from the
generalized proinflammatory environment associated
with infections could facilitate the destruction of hypo-
cretin-secreting neurons in a variety of ways. Strepto-
coccal infections can induce the production of IL-17 by
T cells, and IL-17 receptor signaling has been shown to
facilitate permeability of the blood–brain barrier, poten-
tially exposing hypocretin-secreting neurons to the
immune system. While the relative contribution of
these immunological processes to disease pathophysiol-
ogy remains unclear, the connection to upper-airway
infections provides additional support for an auto-
immune basis of narcolepsy.
Increased onset of narcolepsy in China
following the H1N1 pandemic of 2009
The correlation between influenza A infection and the
onset of narcolepsy was further strengthened by reports
from China showing that onset in children was highly
correlated with seasonal patterns of upper airway infec-
tions, including a spike in diagnosis following the
H1N1 influenza pandemic of 2009 [24], a phenom-
enon that was followed by a decrease in cases in the
years that followed [26]. Intriguingly, the vast majority
(>95%) of patients diagnosed with narcolepsy follow-
ing the 2009 pandemic had not received H1N1 vacci-
nation, indicating that naturally occurring influenza A
infections may increase the susceptibility of develop-
ing this disorder. As most of the newly reported cases
were young children following upper-airway  infections,
important questions have arisen regarding the specific
immunological responses generated in these young
individuals that may have increased their risk of devel-
oping narcolepsy.Current Opinion in Neurobiology 2013, 23:767–773 While these findings are of extreme interest to our un-
derstanding of narcolepsy, the connection between in-
fection and onset is not a novel observation. Kinnier
Wilson also described a cohort of similar new cases of
narcolepsy due to the worldwide epidemic of encephalitis
from about 1918 to 1925 secondary to the Spanish flu
pandemic (Wilson SAK: The narcolepsies. Brain 1928,
51:63–109).
Pandemrix vaccination connected to
narcolepsy in Scandinavia
Reports from Scandinavia first suggested the possibility
that the development of narcolepsy could have been
triggered by H1N1 vaccination [27]. Recent studies have
indicated that Pandemrix, an AS03 (squalene, alpha-
tocopherol) H1N1 vaccine developed in response to
the 2009 H1N1 influenza pandemic, likely contributed
to the spike of narcoleptic onset seen among children and
young adults in Finland [28]. Finnish researchers
reported a 12.7-fold increased risk of narcoleptic diagnosis
in children and young adults approximately eight months
following Pandemrix vaccination when compared to age-
matched individuals that did not receive the vaccination
[28,29]. Further reports revealed an association in
Sweden, Finland, Ireland and in the UK following the
AS03-adjuvanted vaccine and an increased risk of devel-
oping narcolepsy mostly increased in individuals between
5 and 19 years of age [28]. Conversely, there have been no
reported increases in the incidence of narcolepsy in Italy,
or the Netherlands, though the reason behind this
phenomenon remains unclear [27]. Much attention has
now been focused on systematically collecting data to
further understand the association between H1N1 infec-
tions/vaccinations and the onset of narcolepsy [30]. What
remains unclear, however is why other H1N1 vaccines,
such as those with squalene alone as an adjuvant (avail-
able in Europe), or non-adjuvanted vaccine (all vaccines
used in the US) did not seem to be as strongly associated,
if associated at all with increased narcolepsy incidence.
Immunological associations of narcolepsy
The importance of the immune system and its potential
role in the onset of narcolepsy has been the focus of
research and debate for many years [31–33]. Much of the
initial supporting evidence was based on strong genetic
linkage to 6p21.3, an incredibly gene-rich region of the
genome that includes a multitude of immunologically
associated genes including the human leukocyte antigen
(HLA) [34]. With more than 98% of narcoleptic patients
with low CSF hypocretin-1 carrying HLA DQB1*06:02,
frequently in combination with HLA DRB1*15:01, nar-
colepsy has one of the strongest known associations with
HLA [35,36]. While nearly all narcoleptic patients
express DQB1*06:02, expression of DQB1*06:02 is not
limited to narcoleptic individuals; between 12% and 38%
of the general population are carriers of this allele [37].www.sciencedirect.com
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HLA-DRB1-DQA1-DQB1 haplotype and several auto-
immune diseases has been previously described, in-
cluding Graves’s disease, rheumatoid arthritis, and type
1 diabetes [38–42]. The significant association with
DQB1*06:02 strongly suggests an interaction between
a specific T cell receptor subtype leading to the destruc-
tion of hypocretin producing neurons.
Other reported immunological associations with narco-
lepsy include polymorphisms in the T cell receptor alpha
(TCRa) locus [43,44,45]. Following somatic DNA
recombination of V, D, and J segments in TCR loci,
alpha and beta chains are generated by developing T
cells to form a unique, antigen-specific heterodimeric
protein called the TCR. Expressed on the surface of T
cells, the TCR plays an integral role in the recognition of
antigens bound to HLA molecules on the surface of
antigen presenting cells (APCs) (Figure 1a, [II]) [46].
Specific variants in the TCR alpha locus J region segment
were shown to confer an increased risk of developing
narcolepsy [43]. These findings in addition to the strong
association with DQB1*06:02 strongly suggest a T cell-
mediated autoimmune basis in the development of nar-
colepsy.
Recent Immunochip studies found that polymorphisms
in Cathepsin H (CTSH), a member of the Cathepsin
family, were also associated with narcolepsy [47]. Cath-
epsins are endosomal/lysosomal enzymes that play an
important role in numerous cellular processes, including
protein recycling, antigen processing, and peptide–MHC
II interactions. CTSH is highly expressed in APCs such as
monocytes, dendritic cells, and B cells. It is reasonable to
hypothesize that changes in CTSH activity could alter
the MHC II–peptide repertoire presented to T cells
leading to an increased risk of developing narcolepsy
(Figure 1a, [II]).
Associations between narcolepsy and polymorphisms
within the Tumor Necrosis Factor (ligand) Superfamily
member 4 (TNFSF4, also called OX40L) were also found
in the same Immunochip study [47]. OX40L is an import-
ant costimulatory molecule that functions to promote T
cell survival, expansion, and effector functions. In
addition, OX40–OX40L interactions have been impli-
cated in the regulation of regulatory T cells, and are
important in maintaining tolerance to prevent autoimmu-
nity. It is possible that altered co-stimulation of T cells
could skew the immune response to infection (Figure 1a,
[III]), thus increasing the risk of developing narcolepsy.
Reports of narcoleptic patients with additional clinical
symptoms including deafness, cerebellar ataxia, and neu-
ropathy have recently been associated with mutations in
the exon 21 of the DNMT1 gene [48]. DNMT1 is a DNA
methyltransferase that is highly expressed in the immunewww.sciencedirect.com system, and has been shown to be important for T
regulatory cell differentiation following TCR stimulation
[49]. The consequences of this mutation on the immune
system for narcoleptic patients is unknown, though an
alteration in T regulatory cell development and or func-
tion is known to result in various autoimmune conditions.
It is also possible that DNMT1 has effect on neurode-
generation.
Further strengthening the case for an autoimmune basis,
a SNP in the 30 untranslated region of P2RY11, a pur-
inergic receptor gene, has also shown strong association
with narcolepsy [45,50]. P2RY11 is an ATP receptor
that modulates leukocyte maturation, chemotaxis, and
apoptosis. Further analysis revealed a correlation between
this P2RY11 allele and reduced expression in cytotoxic
lymphocytes as well as natural killer (NK) cells. Reduced
expression of P2RY11 could lead to reduced resistance to
ATP-mediated cell death, potentially altering the
immune response to infection (Figure 1a, [IV]), or
possibly directly effecting hypocretin-secreting neurons.
Interestingly, P2RY11 is located extremely close to
DNMT1, and this proximity (synteny) is conserved in
phylogeny up to zebrafish, suggesting that these two
genes may have common or intertwined regulatory
elements.
Researchers have long searched for evidence of hypocre-
tin-specific antibodies as a possible mechanism of the
specific destruction of hypocretin-producing neurons in
the brain. Many of the findings were either negative or
inconclusive, though a humoral contribution cannot be
completely ruled out as an important component [33].
Recent studies have shown altered levels of total IgG and
hypocretin-specific IgM in narcoleptic patients, though
these findings were not specific to patients with low levels
of hypocretin [51,52]. Using a transgenic mouse model to
identify proteins co-localized with hypocretin, research-
ers were able to detect autoantibodies against tribbles
homologue 2 (TRIB2) in the serum of 14% of narcoleptic
individuals compared to 5% in controls [53]. This obser-
vation was replicated in multiple ethnic groups and anti-
TRIB2 autoantibodies were associated with the onset of
narcolepsy [54,55], although not in post H1N1 cases.
While TRIB2 is highly expressed by hypocretin produ-
cing neurons, TRIB2 can be found in many other cell
types, indicating this is unlikely the causative mechanism
that results in the specific destruction of hypocretin
producing neurons (Figure 1a, [IV]) [56].
Autoimmunity and narcolepsy
An autoimmune basis for the hypocretin cell loss in
narcolepsy has long been suspected due to its strong
genetic association with selected HLA alleles. HLA
encodes multiple subtypes of MHC class I and II proteins
that present foreign peptides to T cells during infections
thereby triggering immune responses via TCR activation.Current Opinion in Neurobiology 2013, 23:767–773
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Autoimmunity and hypocretin cell loss. (I) Following phagocytosis, APCs degrade H1N1 influenza virus in the lysosome, a process facilitated by
Cathepsin H. (II) Peptides from the virus are presented on the surface of APCs in the context of MHC class II (DQA1*01:02-DQB1*06:02) for cognate
TCR recognition. (III) Hypocretin specific CD4+ T cells recognizes the presented antigen and is activated. After being activated, the CD4 + T cells
upregulate the expression of OX40 which is an important costimulatory molecule recognized by APCs that express OX40L. (IV) Activated CD4+ T cells
secrete IFN-g, TNF-a and IL-2, which stimulate CD8+ T cells and drive a Th1 mediated immune response. IL-4 from activated CD4+ T cells promotes a
humoral response leading to the production of Tribbles2 antibody by B cells. (V) Generation of super antigens as a result of streptococcus infection
activates Th17 cells, facilitating the breakdown of the blood–brain barrier through the secretion of IL-17 and IL-22. Increased permeability allows for the
migration of activated T cells, B cells, and TRIBBLES2 antibodies into the CNS. (VI) Migration of activated T cells and B cells through the BBB is
followed by interaction with CNS APCs (microglia) that present autoantigens (hypocretincell autoantigens) in the context of DQA1*01:02-DQB1*06:02.
(VII and inset c) Reactivated T cells reach the hypothalamus and recognize hypocretin neurons, inducing effector functions such as the secretion of
cytokines or cytotoxic compounds. Moreover, superantigens from streptococcus cross-link the MHC and TCR molecules independent of antigen
specificity activating the autoreactive T cell. This may lead to sensitization to hypocretin-specific antigens and form the basis for subsequent booster
reactions of cross-reactive CD4+ T cells, a process that finally will end in an autoimmune reaction against hypocretin neurons. APC, antigen presenting
cell; MCH, melanin concentrating hormone; MHC, major histocompatibility complex; TCR, T cell receptor.
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takenly perceived as foreign, thus leading to tissue
destruction, which often occurs in context of specific
HLA alleles.
Among autoimmune diseases, narcolepsy is uniquely
positioned to demonstrate molecular mimicry in humans.
First, narcolepsy occurs nearly exclusively in individuals
with DQB1*06:02. Second, a specific association with the
TCRa locus also confers an increased risk, indicating a
crucial role for specific J segments of TCRa in theFigure 2
Endocytosis
Cross reactivity
Antigen presentation
Antigen selection
H1N1 2009
APC
Naive
T-cell
Effector
T-cell
Hcrt
neuron
Endosome
Endosome
(a) (b
(c) (d
(e) (f
(g) (h
Invariant 
chain
MHC II
TCR
Molecular mimicry between H1N1 peptides and hypocretin neuron autoanti
peptides are required for molecular mimicry to occur. (a) The H1N1 virus is
peptide fragments in the endosome/lysosome. (b) The invariant chain is dig
fragment. (c,d) The MHC binding groove selects the H1N1 fragment with a s
(e) The vesicles move to the plasma membrane and the complex is display
presented peptide with a specific amino acid sequence. (g,h) Activated CD
foreign molecules, prompting an autoimmune response against hypocretin n
www.sciencedirect.com ‘immunological synapse’ of narcolepsy (Figure 1a, [II]).
Finally, studies have shown increased rates of narcoleptic
onset in children following exposure to influenza A H1N1
infections and selected H1N1 vaccine preparations.
These findings strongly suggest that some T cells that
can be activated by H1N1 epitopes that leads to the
destruction of hypocretin-producing neurons
(Figure 1b, [VII]). A parsimonious explanation could
involve mimicry between H1N1 and a peptide contained
in hypocretin cells (Figure 2g and b). Many cofactors have
recently been identified as co-localizing with hypocretinH1N1 peptides
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gens. Sequence and structural homology between foreign and self-
 engulfed by an APC and the foreign antigenic material is digested into
ested and the MHC groove is ready for occupancy by the antigenic
pecific amino acid sequence in the context of DQA1*01:02-DQB1*06:02.
ed at the cell surface for TCR recognition. (f) The TCR recognizes a
4+ T cells cross-react and recognize hypocretin neuron autoantigens as
eurons. MHC, major histocompatibility complex; TCR, T-cell receptor.
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vaccine was particularly associated with increased onset
could be the result of the strength and nature of the AS03
adjuvant that would catalyze molecular mimicry between
H1N1 proteins and hypocretin-cell containing proteins.
Controversy still remains regarding the likely contri-
bution of the immune system to the development of
narcolepsy. Neither key targets of immune cells nor a
molecular mechanism to explain how the immune system
is responsible for the specific depletion of hypocretin-
producing neurons has yet been identified. While the
body of evidence clearly implicates the immune system,
future studies will be required to confirm the auto-
immune basis of narcolepsy. We believe that one of
the reasons why the mechanism may be so difficult to
detect is an absence of epitope spreading and autoanti-
bodies in the disease. This may however turn out to be an
advantage eventually, as if the autoimmune process is
finally discovered, it is more likely to be closer to
causality.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.conb.2013.04.013.
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